Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Mallinckrodt
Dow
Colorcon
Harvard Business School

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR RIVASTIGMINE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Rivastigmine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000174 ↗ Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx) Completed Novartis Phase 3 1969-12-31 This phase IIIb trial is a prospective, randomized, double-blind, placebo-controlled, 36-month study comparing the length of time of progression from mild cognitive impairment (MCI) to a clinical diagnosis of Alzheimer's disease (AD) in subjects taking Exelon vs. placebo. Exelon is currently under review with the U.S. Food and Drug Administration as a treatment for Alzheimer's disease. The drug has been cleared for marketing in more than 40 countries for Alzheimer's disease to date, including all 15 member states of the European Union, New Zealand, Argentina, Brazil and Mexico. Each subject with MCI will be randomly assigned to treatment with either Exelon or placebo. Subjects assigned to Exelon will receive 1.5 to 6.0 mg bid (twice daily) (3.0 to 12 mg/day) for the majority of the study. At every regular visit scheduled every three months, patients will be given basic efficacy and safety assessments. These assessments will include evaluation of adverse events, vital signs, activities of daily living, and clinical staging scales to determine if the subject may have converted to dementia.
NCT00099216 ↗ Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed Novartis Pharmaceuticals Phase 3 2001-08-01 The goal of this research study is to evaluate the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.
NCT00099242 ↗ Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease Completed Novartis Phase 3 2003-11-01 The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Rivastigmine

Condition Name

Condition Name for Rivastigmine
Intervention Trials
Alzheimer's Disease 32
Alzheimer Disease 12
Delirium 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Rivastigmine
Intervention Trials
Alzheimer Disease 51
Dementia 20
Cognitive Dysfunction 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Rivastigmine

Trials by Country

Trials by Country for Rivastigmine
Location Trials
United States 198
Japan 46
Canada 22
Italy 20
Netherlands 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Rivastigmine
Location Trials
Texas 14
California 13
New York 12
Florida 12
Pennsylvania 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Rivastigmine

Clinical Trial Phase

Clinical Trial Phase for Rivastigmine
Clinical Trial Phase Trials
Phase 4 34
Phase 3 30
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Rivastigmine
Clinical Trial Phase Trials
Completed 74
Terminated 10
Recruiting 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Rivastigmine

Sponsor Name

Sponsor Name for Rivastigmine
Sponsor Trials
Novartis 21
Novartis Pharmaceuticals 15
National Institute on Drug Abuse (NIDA) 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Rivastigmine
Sponsor Trials
Other 106
Industry 59
NIH 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
AstraZeneca
Merck
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.